TARS · Tarsus Pharmaceuticals Inc
United States · RS rating 75 · As of 2026-11-03
| Price | 72.64 USD |
|---|---|
| 1-day change | -0.9% |
| RS rating (overall / 1M / 3M / 12M) | 75 / 50 / 89 / 56 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 43 / 31 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +33.3% |
| Sales growth Q/Q | +27.8% |
| Distance from 52-week high | +20.0% |
| Market cap (USD) | $2.6B |